Northland Securities reissued their buy rating on shares of Intrexon Corporation (NYSE:XON) in a research report report published on Friday. The firm currently has a $27.00 target price on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on the company. BidaskClub raised Intrexon Corporation from a strong sell rating to a sell rating in a research report on Thursday, June 15th. Griffin Securities reissued a buy rating and set a $55.00 price target on shares of Intrexon Corporation in a research report on Friday. Zacks Investment Research downgraded Intrexon Corporation from a hold rating to a sell rating in a research report on Thursday, July 13th. Finally, JMP Securities reaffirmed an outperform rating and issued a $42.00 target price on shares of Intrexon Corporation in a research report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Intrexon Corporation currently has a consensus rating of Hold and an average target price of $43.20.

Shares of Intrexon Corporation (NYSE XON) opened at 18.88 on Friday. The company’s 50-day moving average price is $19.12 and its 200 day moving average price is $21.12. Intrexon Corporation has a 52 week low of $17.03 and a 52 week high of $32.90. The company’s market cap is $2.28 billion.

Intrexon Corporation (NYSE:XON) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. The firm had revenue of $54.40 million for the quarter, compared to the consensus estimate of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The business’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.42) earnings per share. On average, equities analysts forecast that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Intrexon Corporation (XON) Given Buy Rating at Northland Securities” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/intrexon-corporation-xon-given-buy-rating-at-northland-securities/1620528.html.

In other news, Director Dean J. Mitchell bought 5,000 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were bought at an average price of $18.33 per share, with a total value of $91,650.00. Following the completion of the transaction, the director now owns 18,103 shares of the company’s stock, valued at $331,827.99. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Andrew J. Last bought 2,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was purchased at an average cost of $19.99 per share, for a total transaction of $39,980.00. Following the transaction, the chief operating officer now directly owns 2,000 shares of the company’s stock, valued at approximately $39,980. The disclosure for this purchase can be found here. Insiders bought 144,569 shares of company stock worth $2,719,429 in the last ninety days. 56.30% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its position in shares of Intrexon Corporation by 60.0% in the first quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock valued at $2,862,000 after purchasing an additional 54,179 shares during the last quarter. Stifel Financial Corp grew its position in shares of Intrexon Corporation by 15.5% in the first quarter. Stifel Financial Corp now owns 60,748 shares of the biotechnology company’s stock valued at $1,209,000 after purchasing an additional 8,135 shares during the last quarter. National Planning Corp grew its position in shares of Intrexon Corporation by 13.4% in the second quarter. National Planning Corp now owns 12,958 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 1,528 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Intrexon Corporation by 7.1% in the second quarter. Bank of New York Mellon Corp now owns 234,139 shares of the biotechnology company’s stock valued at $5,640,000 after purchasing an additional 15,568 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its position in shares of Intrexon Corporation by 3.3% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 82,670 shares of the biotechnology company’s stock valued at $1,639,000 after purchasing an additional 2,645 shares during the last quarter. 82.11% of the stock is currently owned by institutional investors.

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.